Results 121 to 130 of about 76,053 (241)

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken   +20 more
wiley   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

open access: yesMedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao   +4 more
wiley   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2560-2570, 15 May 2026.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze   +19 more
wiley   +1 more source

A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs

open access: yesBMC Veterinary Research
Background Capecitabine is an oral prodrug of the active metabolite 5-fluorouracil, which has been used effectively in human colorectal, head and neck, and mammary carcinomas.
Sarah Wetzel   +3 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen   +7 more
wiley   +1 more source

Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 3, Page 710-721, May 2026.
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi   +9 more
wiley   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1457-1472, May 2026.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo   +10 more
wiley   +1 more source

Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer [Dermatomiozitis kao paraneoplastički sindrom peritonealnog i ovarijalnog relapsa nakon dugog perioda potpune remisije u bolesnice s metastatskim bilateralnim rakom dojke] [PDF]

open access: yes, 2012
Dermatomyositis is a rare disease characterised by inflammatory muscle affection and characteristic cutaneous changes. When occuring in a patient with cancer, dermatomyositis may indicate recurrence or progression and poor outcome.
Bolanča, Ante   +5 more
core  

Impact of Physical Frailty on Early Intolerance to CAPOX Chemotherapy in Patients With Colon, Rectal, and Gastric Cancer

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Patients with gastrointestinal cancer often present reduction in functional capacity and develop frailty, which increases the risk of chemotherapy intolerance. We investigated whether physical frailty is associated with early intolerance to CAPOX (capecitabine+oxaliplatin) in patients with colon, rectal, or gastric cancer.
Isabella Pellegrini Grama Pereira Lima   +9 more
wiley   +1 more source

Predicting Prognosis for Gastric Cancer Patients Receiving Neoadjuvant Treatment With Body Composition‐Based Deep Learning

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background This study sought to develop an innovative body composition (BC)‐based deep learning (DL) model to precisely evaluate survival in gastric cancer (GC) patients undergoing neoadjuvant treatment (NT). Materials and Methods This retrospective study included GC patients undergoing NT from two centers.
Yingjing Zhang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy